Treatment options for patients with rare disease are limited|Mark Diamond,CEO,Antisense Therapeutics Ltd 00:10:00
Mark Diamond has over 30 years of experience in the pharmaceutical and biotechnology industry.Before joining Antisense Therapeutics Limited as managing director and chief executive in October 2001, Мг Diamond was with Faulding Pharmaceuticals as senior manager of business development and In-licensing for its European operation based in the UK, international business development manager in Australia, and director of project planning and business development in the US.
